Search Videos and More
News
New Criteria to Assess Progression in Glioma Aims to Speed Discovery of New Medicines
In order to accurately assess the efficacy of novel therapies for brain tumors it is necessary to have reliable criteria to determine response or progression.
News
Final Overall Study Analysis Continues to Show Benefit of Sacituzumab Govitecan in Advanced HR+ Breast Cancer
A novel antibody-drug conjugate continues to demonstrate superior benefit for patients with HR+, HER2- metastatic breast cancer when compared to standard chemotherapy, according to a new study in The Lancet.
News
Cell Therapy That Repairs Cornea Damage with Patient’s Own Stem Cells Achieves Positive Phase I Trial Results
A team led by researchers from Dana-Farber Cancer Institute and Mass Eye and Ear, a member of Mass General Brigham, reports the results of a phase I trial of a revolutionary stem cell treatment called cultivated autologous limbal epithelial cell transplantation (CALEC), which was found to be safe and well-tolerated over the short term in four patients with significant chemical burns in one eye.
News
Errant Cell Division Can Lead to Changes in Gene Activity, Study Finds
There are several ways to ruin a tune: play the wrong notes, play them at the wrong time, or with the wrong emphasis.
News
Live Cell Imaging IDs Bad Actors in Cancer and Finds Possible Ways to Defeat Them
Most forms of chemotherapy are designed to kill cancer cells. But some cancer cells survive. Those that do can cause the cancer to relapse.
News
Origins of Glioma Brain Cancer Found to be in the Epigenome
While cancers often originate from mutations and other alterations of cells' DNA, researchers in the Bernstein Laboratory at Dana-Farber and the Broad Institute of MIT and Harvard have found that gliomas – incurable brain tumors – can arise due to changes in the epigenome, the collection of compounds that are deposited on DNA and alter gene activity without changing the sequence of DNA itself.
News
Obesity and High Weight Linked to Adverse Outcomes In Leukemia Treatment
As the United States faces a growing obesity epidemic, scientists are taking a closer look at how body weight can affect health outcomes.
News
Study Suggests Lymphoma Patients with Depression or Anxiety Experience Shorter Survival Times
Patients with depression and/or anxiety prior to a diagnosis of diffuse large B-cell lymphoma (DLBCL) had shorter survival times than patients without a mental health diagnosis, according to a retrospective study led by Dana-Farber Cancer Institute researchers and published in The Lancet Hematology.
News
Study Uncovers Role of Ultraviolet Radiation in Development of Rare Leukemia in the Skin
A change of scenery can restore one's outlook, but for some precancerous cells, a journey from the caves of the bone marrow to the sunny climes of the skin can trigger genetic changes that are a harbinger of cancer, according to a new study by researchers at Dana-Farber Cancer Institute, Brigham and Women's Hospital, and the Broad Institute of MIT and Harvard.
News
New Clinical Tool for Clonal Hematopoiesis Identifies Patients at High Risk for Blood Cancer
A new clinical tool developed by a team of researchers led by the Dana-Farber Cancer Institute pinpoints which Clonal hematopoiesis patients are at highest risk for cancer progression.
News
High Concentrations of Immune Cells Within Tumors Associated with Longer Patient Survival
ImmunoPROFILE: A prospective implementation of clinically validated, quantitative immune cell profiling test identifies tumor-infiltrating CD8+ and PD-1+ cell densities as prognostic biomarkers across a 2,023 patient pan-cancer cohort treated with different therapies
News
Clinical Trial Shows That Adding Bevacizumab to Targeted Drug and Chemotherapy Produces Striking Activity Against HER2-Positive Metastatic Gastroesophageal Adenocarcinoma
Long-term results and ctDNA correlatives for CAPOX BETR: A multi-center phase II trial of capecitabine, oxaliplatin, bevacizumab and trastuzumab for previously untreated HER2 positive metastatic gastroesophageal adenocarcinoma